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Pathophysiology of Heart Failure 
Mihai Gheorghiade, MD,* and Jeffrey B. Lakier, MD* 
Heart failure occurs when the heart is unable to maintain a cardiac output sufficient to satisfy the 
oxygen requirements of the body despite adequate blood volume and hemoglobin content. Regardless 
ofthe initial cause of heart failure and in spite of compensatory mechanisms, patients often follow a 
course of worsening heart failure that is characterized by a low cardiac output, high filling pressures, 
and increased peripheral vascular resistance. In addition to persistence of the initiating event, 
cardiac deterioration may be caused or aggravated by a variety of factors including depletion 
of cardiac norepinephrine stores, down-regulation of myocardial beta-adrenergic receptors, 
microvascular spasm with resultant further cellular necrosis, and subendocardial ischemia 
perpetuating myocardial failure. (Henry Ford Hosp MedJ 1986:34:153-5) 
H eart failure occurs when the heart is unable to maintain a cardiac output sufficient to satisfy the oxygen requirements 
of the body despite adequate blood volume and hemoglobin con-
tent ( I ) . Myocardial failure, heart failure without myocardial 
failure (eg, tricuspid stenosis and constrictive pericarditis which 
interfere with cardiac filling, or rhythm disturbances), and cir-
culatory volume overload resulting from abnormal salt and 
water retention without a disturbance of cardiac function per se 
(2) all may result in the clinical syndrome of heart failure. This 
review focuses on the pathophysiology of heart muscle dysfunc-
tion that causes myocardial failure. 
Myocardial Failure 
Three different mechanisms may be responsible for myocar-
dial failure (3): 1) primary myocardial failure (cardiomyopathy) 
in which cardiac contractility is severely compromised second-
ary to either a quantitative loss of myocardial cells due to 
destmction or replacement and/or a qualitative defect in myocar-
dial cells; 2) failure due to pressure overload (ie, in aortic ste-
nosis) in which the principal cause of the reduced stroke volume 
is obstmction to ventricular ejection; and 3) failure due to vol-
ume overload in which a significant portion of the total ejected 
cardiac output fails to reach the peripheral tissues due to re-
gurgitation into the atrium (mitral regurgitation) or into the ven-
tricle (aortic regurgitation) (Figure), 
Despite considerable effort directed toward clarifying the 
fundamental processes involved in myocardial contractile dete-
rioration, a distinct biochemical defect responsible for heart 
failure has not been identified (4). 
Myocardial failure, which frequently develops gradually, is 
preceded by a phase in which the whole heart, or the remaining 
viable portion, hypertrophies and dilates (5). This permits com-
pensation for the loss of myocardial cells or hemodynamic over-
load. Why the initial compensatory hypertrophy and dilatation 
progress to myocardial failure is unknown (6). Available data 
suggest that the alteration in the function of myocardial cells and 
not their increased size is responsible for this course of events 
(5). Chronic ischemia (7,8), mitochondrial dysfunction (9), de-
pletion of myocardial energy supplies (10), defective myocardial 
energy utilization (11), and abnormalities in excitation-contrac-
tion coupling (12) are all possible mechanisms. Recent interest 
has focused on the role of abnormalities in calcium transport in 
heart failure (13), Theoretically, defective calcium transport 
could intenupt maximal excitation-contraction coupling by sev-
eral mechanisms: decreased calcium availability to the sar-
colemma, decreased calcium transport across this membrane, 
altered calcium release or uptake by the intracellular sarco-
plasmic reticulum, or decreased calcium removal from the con-
tractile protein. 
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Figure—Pathophysiology of heart failure. *Persistence of a pri-
mary etiology for the initial event (eg, alcohol, aortic stenosis, 
persistent ischemia) will result in further deterioration. 
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Compensatory Mechanisms 
Regardless of the etiology of heart failure, several circulatory 
adjustments tend to compensate for the fall in cardiac output. 
The initial adjustment to a decrease in contractility or volume 
overioad is cardiac dilatation. As the preload increases, a limited 
increase occurs in sarcomere length, and additional sarcomeres 
are recmited to augment ventricular function. This represents 
the Frank-Stariing mechanism (14), However, this mechanism 
may not operate in patients with severely dilated ventricles when 
further ventricular dilatation may cause secondary mitral or tri-
cuspid insufficiency (15,16) and increase in wall tension which 
may further reduce stroke volume (17). In addition, subendocar-
dial ischemia may supervene (18). 
A second compensatory mechanism is fluid retention. Plasma 
volume is increased due to reabsorption of salt and water by the 
kidneys (3), The origins of the sodium retention include eleva-
tions in renal venous pressure, redistribution of the diminished 
renal blood flow toward the juxtamedullary nephron, activation 
of the renin-angiotensin-aldosterone system (19), and lack ofthe 
natriuretic substance. In chronic heart failure, antidiuretic hor-
mone titers are high despite augmented stretch of left atrial 
receptors which normally inhibit the release of this hormone 
(20-22), 
Circulating catecholamines (23) which augment myocardial 
contractility and blood pressure comprise a third mechanism. 
Finally, myocardial hypertrophy (24) may occur, providing a 
fundamental compensatory mechanism when an excessive pres-
sure or volume load is imposed on the heart. 
Regardless of the initial cause of heart failure and despite 
compensatory mechanisms, patients often follow a course of 
worsening heart failure that is characterized by a low cardiac 
output, high filling pressures, and increased peripheral vascular 
resistance (25), 
Possible Causes for Further 
Myocardial Deterioration 
In addition to persistence or progression of the initiating 
event, cardiac deterioration may be caused or aggravated by a 
variety of factors including depletion of cardiac norepinephrine 
stores, down-regulation of myocardial beta-adrenergic recep-
tors, microvascular spasm with resultant further cellular ne-
crosis, and subendocardial ischemia perpetuating myocardial 
failure (Figure), 
Depletion of cardiac norepinephrine stores 
The role of catecholamines in heart failure is discussed in 
detail by Goldstein in this issue of the Journal (26). Control 
subjects have a modest adrenergic tone, low levels of plasma 
catecholamines, and a significant store of myocardial norepi-
nephrine (25). With mild degrees of heart failure, plasma 
catecholamine levels rise only moderately, and myocardial nor-
epinephrine supplies are not depleted (25). With chronic severe 
heart failure, plasma catecholamines are increased markedly 
and myocardial norepinephrine stores are diminished (27). 
Experimentally, after the production of heart failure in dogs 
(28), ventricular norepinephrine concentration falls markedly 
and the infusion of norepinephrine does not raise cardiac nor-
epinephrine stores. The reduced capacity to retain administered 
norepinephrine is probably due to a reduction in the total num-
ber of neurones in the heart (1). This may be responsible for loss 
of the adrenergic support which could intensify the severity of 
the heart failure. 
Down-regulation of beta-receptors 
Compensatory adrenergic stimulation in patients with heart 
failure occurs for a limited period (29). In chronic heart failure 
the activity of endogenous catecholamines is rapidly terminated 
through uptake into intraneuronal and extraneuronal sites where 
metabolic degradation occurs (29). Brief exposure to adrenergic 
agonists transforms the active form of the beta-adrenergic recep-
tor to a low-affinity form that interferes with production of ade-
nylate cyclase (30). Prolonged exposure to adrenergic agonists 
results in a significant decrease in beta-receptor density in 
the cell membrane. This phenomenon is called receptor down-
regulation (29). Because of a decrease in beta-receptor density, 
circulating catecholamines no longer stimulate the failing heart 
to the same degree, and myocardial failure progresses (30,31). 
The high levels of catecholamine observed in patients with se-
vere heart failure (32) in the presence of decreased beta-recep-
tors on cell membranes of smooth muscle may actually reduce 
cardiac output by increasing peripheral resistance through unop-
posed alpha-adrenergic stimulation. Available data suggest that 
there could be a group of patients with heart failure in whom 
long-term beta-adrenergic blockade will improve myocardial 
function and prolong life (33,34). The benefit that has been 
observed from beta-blocker therapy may be the result of up-reg-
ulation of beta-adrenergic receptors, allowing restoration of 
catecholamine responsiveness which results in improved myo-
cardial function. 
Microvascular spasm 
Dilated cardiomyopathy may possibly begin with focal tran-
sient microvascular spasm that causes myocyte necrosis and, 
subsequently, fibrosis (35), Factor et al (36) showed that the Syr-
ian hamster develops focal myocardial necrosis beginning at one 
month of age, which leads to eventual ventricular failure within 
one year. Those authors demonstrated that transient spasm of 
small blood vessels, probably secondary to vasoactive sub-
stances, may cause myocytolytic necrosis. According to Son-
nenblick et al (35), verapamil, a channel calcium antagonist, 
prevents the focal necrosis and fibrosis in the Syrian hamster 
myocardium. The similarity of this disease to human and experi-
mental cardiomyopathy suggests that microvascular spasm may 
be a common denominator in many different cardiomyopathic 
syndromes. The perfusion defects (37) seen on thallium-201 
scans of patients with idiopathic dilated cardiomyopathy may 
represent areas of myocardial fibrosis and scaning resulting 
from micro vasospasm. 
Subendocardial ischemia 
Studies (38,39) suggest that in patients with a dilated car-
diomyopathy the subendocardial muscle first loses its ATP, fol-
lowed by vacuolization and finally fibrosis. This progressive 
deterioration can be due partly to insufficient coronary blood 
flow to the subendocardium, which initiates a vicious cycle 
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that worsens the heart failure and further decreases coronary 
blood flow (18), This hypothesis has some implications in the 
therapeutics of heart failure. Decreasing ventricular size, lower-
ing left ventricular end-diastolic pressure, or decreasing heart 
rate may improve subendocardial perfusion and conect the 
imbalance of energy supply and demand (39), Benefits of beta-
blocker therapy in patients with idiopathic dilated cardiomyopa-
thy (33) may be partly related to increased subendocardial flow 
resulting from an increase in diastolic time (decreased heart 
rate) and transmural redistribution of blood from the subepicar-
dium to the subendocardium (40), 
In the last ten years important progress has been made in the 
development of pharmaceutical agents for the management of 
patients with chronic heart failure. Research has been directed 
toward improving abnormal hemodynamics in these patients. 
Although symptomatic improvement may result from the aug-
mentation of cardiac output when inotropic and vasodilating 
agents are employed, survival may not be altered (31). Survival 
is determined by the amount of myocardial damage and its pro-
gression, which may not be affected by such agents (41). To have 
a favorable impact on duration as well as quality of life, future 
research will need to focus on not only improving cardiac hemo-
dynamics but also preventing further myocardial cell loss or 
dysfunction, especially in the early stages of heart failure. 
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